BlackRock, Inc. 13D and 13G filings for Keros Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-01-26 5:26 pm Purchase | 2023-12-31 | 13G | Keros Therapeutics, Inc. KROS | BlackRock Inc. BLK | 2,036,788 6.800% | 398,462 (+24.32%) | Filing |
| 2023-02-07 11:06 am Purchase | 2022-12-31 | 13G | Keros Therapeutics, Inc. KROS | BlackRock Inc. BLK | 1,638,326 5.900% | 351,800 (+27.34%) | Filing |
| 2022-02-03 4:29 pm Purchase | 2021-12-31 | 13G | Keros Therapeutics, Inc. KROS | BlackRock Inc. BLK | 1,286,526 5.500% | 87,325 (+7.28%) | Filing |
| 2021-02-02 3:13 pm Purchase | 2020-12-31 | 13G | Keros Therapeutics, Inc. KROS | BlackRock Inc. BLK | 1,199,201 5.200% | 1,199,201 (New Position) | Filing |